ES2176296T3 - Composiciones farmaceuticas que permiten la liberacion prolongada de trimetacidina despues de la administracion por via oral. - Google Patents

Composiciones farmaceuticas que permiten la liberacion prolongada de trimetacidina despues de la administracion por via oral.

Info

Publication number
ES2176296T3
ES2176296T3 ES95400628T ES95400628T ES2176296T3 ES 2176296 T3 ES2176296 T3 ES 2176296T3 ES 95400628 T ES95400628 T ES 95400628T ES 95400628 T ES95400628 T ES 95400628T ES 2176296 T3 ES2176296 T3 ES 2176296T3
Authority
ES
Spain
Prior art keywords
trimetacidine
allow
pharmaceutical compositions
prolonged
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95400628T
Other languages
English (en)
Inventor
De Barochez Bruno Huet
Patrick Genty
Alain Cuine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Application granted granted Critical
Publication of ES2176296T3 publication Critical patent/ES2176296T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE PERMITEN LA LIBERACION PROLONGADA DE TRIMETACIDINA TRAS LA ADMINISTRACION POR VIA ORAL.
ES95400628T 1994-03-24 1995-03-22 Composiciones farmaceuticas que permiten la liberacion prolongada de trimetacidina despues de la administracion por via oral. Expired - Lifetime ES2176296T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403434A FR2717687B1 (fr) 1994-03-24 1994-03-24 Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale.

Publications (1)

Publication Number Publication Date
ES2176296T3 true ES2176296T3 (es) 2002-12-01

Family

ID=9461361

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95400628T Expired - Lifetime ES2176296T3 (es) 1994-03-24 1995-03-22 Composiciones farmaceuticas que permiten la liberacion prolongada de trimetacidina despues de la administracion por via oral.

Country Status (15)

Country Link
EP (1) EP0673649B1 (es)
JP (1) JP3017040B2 (es)
CN (1) CN1056057C (es)
AT (1) ATE216583T1 (es)
AU (1) AU684893B2 (es)
CA (1) CA2145248C (es)
DE (1) DE69526467T2 (es)
DK (1) DK0673649T3 (es)
ES (1) ES2176296T3 (es)
FI (1) FI116881B (es)
FR (1) FR2717687B1 (es)
NO (1) NO306450B1 (es)
NZ (1) NZ270791A (es)
PT (1) PT673649E (es)
ZA (1) ZA952418B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
EP1195160B1 (en) * 2000-10-05 2009-09-16 USV Ltd. Sustained release trimetazidine pharmaceutical compositions and a method of their preparation
FR2818549B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Composition pharmaceutique solide thermoformable pour la liberation controlee de trimetazidine
HUP0500382A3 (en) * 2001-11-21 2008-03-28 Themis Lab Private Ltd Sustained release pharmaceutical compositions containing microbeads of trimetazidine dihydrochloride and process for producing them
FR2885807B1 (fr) * 2005-05-18 2008-05-16 Mg Pharma Composition pharmaceutique solide a liberation prolongee de 1-(2,3,4-trimethoxybenzyl) piperazine, et procede de preparation
WO2007116243A2 (en) * 2006-04-10 2007-10-18 Mintails Limited Method for treating fibromyalgia and related conditions
EP2200591A2 (en) 2007-09-11 2010-06-30 Ranbaxy Laboratories Limited Controlled release pharmaceutical dosage forms of trimetazidine
EP2389167A2 (en) 2009-01-20 2011-11-30 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
EP2391353B1 (en) * 2009-01-30 2016-02-10 Lupin Limited Pharmaceutical compositions of trimetazidine
TR201001902A2 (tr) 2010-03-12 2011-04-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salınımlı trimetazidin tablet
US20110274751A1 (en) 2010-05-04 2011-11-10 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Trimetazidine formulation with different release profiles
EP2386302A1 (en) 2010-05-11 2011-11-16 Ranbaxy Laboratories Limited A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof
BG1345U1 (bg) * 2010-05-20 2010-08-31 "Адифарм" Ад Лекарствена форма с изменено освобождаване
EP2491930A1 (en) 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Pharmaceutical combination of betahistine and trimetazidine
CN102133195A (zh) * 2011-03-17 2011-07-27 王国栋 盐酸曲美他嗪的缓控释微丸及其制备方法
CN102319225B (zh) * 2011-09-23 2013-04-03 广州白云山光华制药股份有限公司 一种盐酸曲美他嗪缓释片及其制备方法
FR2986431B1 (fr) * 2012-02-03 2017-03-17 Servier Lab Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques
CN102764261A (zh) * 2012-07-30 2012-11-07 沈阳药科大学 口服控制盐酸曲美他嗪释放的组合物及其制备方法
CN103565751A (zh) * 2013-10-17 2014-02-12 广州帝奇医药技术有限公司 一种长效缓释微丸及其制备方法
US20190381034A1 (en) * 2018-06-14 2019-12-19 Ming Fang Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
CN110237053A (zh) * 2019-07-26 2019-09-17 湖北欣泽霏药业有限公司 一种盐酸曲美他嗪缓释微丸及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2490963B1 (fr) * 1980-09-30 1986-04-18 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
DE3686275T2 (de) * 1985-01-11 1993-03-18 Teijin Ltd Praeparate mit verzoegerter freisetzung.
JPH0625055B2 (ja) * 1985-03-18 1994-04-06 日本ケミフア株式会社 持続性錠剤
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
US5417983A (en) * 1992-02-19 1995-05-23 Sagami Chemical Research Center Drug release controlling material responsive to changes in temperature

Also Published As

Publication number Publication date
FR2717687A1 (fr) 1995-09-29
CN1124140A (zh) 1996-06-12
JPH07258086A (ja) 1995-10-09
NO951110D0 (no) 1995-03-23
NZ270791A (en) 1996-07-26
NO306450B1 (no) 1999-11-08
EP0673649A1 (fr) 1995-09-27
FI951357A0 (fi) 1995-03-22
DE69526467D1 (de) 2002-05-29
NO951110L (no) 1995-09-25
FI951357L (fi) 1995-09-25
CA2145248C (fr) 2004-01-06
PT673649E (pt) 2002-08-30
CA2145248A1 (fr) 1995-09-25
AU684893B2 (en) 1998-01-08
ATE216583T1 (de) 2002-05-15
FI116881B (fi) 2006-03-31
EP0673649B1 (fr) 2002-04-24
FR2717687B1 (fr) 1996-06-14
DK0673649T3 (da) 2002-08-05
DE69526467T2 (de) 2002-12-05
ZA952418B (en) 1995-12-18
JP3017040B2 (ja) 2000-03-06
CN1056057C (zh) 2000-09-06
AU1502995A (en) 1995-10-05

Similar Documents

Publication Publication Date Title
HN1999000066A (es) Formulaciones farmaceuticas
ES2161049T3 (es) Composicion farmaceutica para administracion oral de un derivado de la n-piperidino-3-pirazolcarboxamida, de sus sales y de sus solvatos.
ES2153964T3 (es) Liberacion controlada de farmacos administrados por via sublingual o bucal.
HN1998000113A (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
ES2184293T3 (es) Composiciones farmaceuticas administrables por via oral que comprenden una benzhidrilpiperazina y una ciclodextrina.
HN1998000086A (es) Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
SV1998000029A (es) Compuestos de pirazina ref. pg3186
ES2160145T3 (es) Composicion farmaceutica para la administracion oral de flavonoides.
ES2083119T3 (es) Comprimido matricial que permite la liberacion prolongada de indapamida despues de su administracion por via oral.
GT199700052A (es) Sales metanosulfonatode5-(2-4-(1,2-benzoisotiazol-3-il)-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-onadihidratadas
ES2169147T3 (es) Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento.
HN1998000160A (es) Sistema constructivo modular hondulog
AR012504A1 (es) Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion.
FI951357L (fi) Farmaseuttiset koostumukset, jotka mahdollistavat trimetatsidiinin hidastetun vapautumisen oraalisen annostuksen jälkeen
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
SE9801494D0 (sv) Novel use
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
SV1998000013A (es) Derivados de 5-aroilnaftaleno ref.-ran 4070\115
UY28422A1 (es) Sistemas emulsionantes que contienen derivados de azetidina
ES2173556T3 (es) Nuevos compuestos heterociclicos, su procedimiento de preparacion y los compuestos farmaceuticos que los contienen.
YU87501A (sh) Farmaceutski kompleksi